Pharmacotherapy of premenstrual syndromes and premenstrual disphoric disorder: current practices

REFERENCES

• AMERICAN PSYCHIATRIC ASSOCIATION: Diagnostic and Statistical Manual of Mental Disorders, 3rd edn, Revised American Psychiatric Press, Inc., Washington DC (1987).
   Google Scholar
• AMERICAN PSYCHIATRIC ASSOCIATION: Diagnostic and Statistical Manua] of Mental Disorders, 4th edn. American Psychiatric Press, Inc., Washington DC (1994).
   Google Scholar
• AMERICAN COLLEGE OF OBSTETRICIANS AND GYNECOLOGISTS (ACOG): Premenstrual Syndrome. ACOG, Washington DC (2000). •A serious, though imperfect attempt to define criteria for diagnosis.
   Google Scholar
• LOGUE CM, MOOS RH: Perimenstrual symptoms: prevalence and risk factors. Psychosom. Med. (1986) 48(0388–414.
   PubMed Web of Science ®Google Scholar
• WOODS NE MOST A, DERY GK: Prevalence of perimenstrual symptoms. Jim. J. Public Health. (1982) 72(11):1257–1264.
   PubMedGoogle Scholar
• WITTCHEN HU, BECKER E, LIEB R, KRAUSE P: Prevalence, incidence and stability of premenstrual dysphoric disorder in the community. Psycho] Med. (2002) 32(1):119–132. ••A comprehensive delineation of prevalenceof PMDD using clinically relevant criteria.
   Google Scholar
• ROBINSON RL, SWINDLE RW: Premenstrual symptom severity: impact on social functioning and treatment-seeking behaviors. I Womens Health Gend. Based Med. (2000) 9(7):757–768.
   PubMed Web of Science ®Google Scholar
• ANGST J, SELLARO R, MERIKANGAS KR, ENDICOTT J: The epidemiology of perimenstrual psychological symptoms. Acta Psychiatr. Scand. (2001) 104(2):110–116.
   PubMed Web of Science ®Google Scholar
• JOHNSON SR: The epidemiology and social impact of premenstrual symptoms. Clin. Obstet. Gynecol (1987) 30(2):367–376.
   PubMed Web of Science ®Google Scholar
• ANDERSCH B, WENDERSTAM C, HAHN L, OHMAN R: Premenstrual complaints. I. Prevalence of premenstrual symptoms in a Swedish urban population. Psychosom. °Enter Gynaecol (1986) 5:39–49.
   Google Scholar
• HALBREICH U, BORENSTEIN J, PEARLSTEIN T, KAHN L: The prevalence, impairment, impact, and burden of premenstrual dysphoric disorder (PMS/PMDD). Psychoneuivendocrinol (In press).
   Google Scholar
• AMERICAN COLLEGE OF OBSTETRICIANS AND GYNECOLOGISTS (ACOG): Premenstrual Syndrome: Committee Opinion No. 66. ACOG, Washington DC (1989).
   Google Scholar
• RAMCHARAN S, LOVE EJ, FICK GH, GOLDFIEN A: The epidemiology of premenstrual symptoms in a population-based sample of 2650 urban women: Attributable risk and risk factors. J. Clin. Epidemiol (1992) 45(4):377–392.
   PubMed Web of Science ®Google Scholar
• ZHAO G, WANG L, QU C: Prevalence of premenstrual syndrome in reproductive women and its influential factors. Chung-Hua Fu Chan Ko La Chih [Chinese I Obst. Gynecoll (1998) 33(4):222–224.
   Google Scholar
• BARNHART KT, FREEMAN EW, SONDHEIMER SJ: A clinician's guide to the premenstrual syndrome. Med. Clin. N Am. (1995) 79(6):1457–1472.
   PubMedGoogle Scholar
• STEINER M: Premenstrual syndromes. Ann. Rev Med. (1997) 48:447–455.
   PubMed Web of Science ®Google Scholar
• DALTON K, DALTON ME, GUTHRIE K: Incidence of the premenstrual syndrome in twins. Br. Med. 1 (1987) 295:1027–1028.
   PubMedGoogle Scholar
• KENDLER KS, SILBERG JL, NEALE MC, KESSLER RC, HEATH AC, EAVES LJ: Genetic and environmental factors in the aetiology of menstrual, premenstrual and neurotic symptoms: a population-based twin study. Psycho] Med. (1992) 22(1):85–100.
   PubMedGoogle Scholar
• KENDLER KS, KARKOWSKI LM, COREY LA, NEALE MC: Longitudinal population-based twin study of retrospectively reported premenstrual symptoms and lifetime major depression. Am. J. Psychiatry(1998) 155(9):1234–1240.
   PubMed Web of Science ®Google Scholar
• LESCH KP, MULLER U, RUPPRECHT R, KRUSE K, SCHULTE HM: Endocrine responses to growth hormone-releasing hormone, thyrotropin-releasing hormone and corticotropin-releasing hormone in depression. Acta Psychiatr. Scand. (1989) 79(6):597–602.
   PubMedGoogle Scholar
• RAPKIN AJ, EDELMUTH E, CHANG LC, READING AE, MCGUIRE MT, SU TP: Whole-blood serotonin in premenstrual syndrome. Obstet. Gynecol (1987) 70 (4):533–537.
   PubMed Web of Science ®Google Scholar
• RAPKIN A, CHUONG LC, READING A, MCGWIRE MT: Tryptophan loading test in premenstrual syndrome. Obstet. Gynecol (1989) 10:140–144.
   Google Scholar
• TAYLOR DL, MATHEW RJ, HO BT, WEINMAN ML: Serotonin levels and platelet uptake during premenstrual tension. Neuropsychobiol (1984) 12(1):16–18.
   PubMedGoogle Scholar
• SU TP, SCHMIDT PJ, DANACEAU M, MURPHY DL, RUBINOW DR: Effect of menstrual cycle phase on neuroendocrine and behavioral responses to the serotonin agonist m-chlorophenylpiperazine in women with premenstrual syndrome and controls. J. Clin. Endocrinol Metab. (1997) 82(4):1220–1228.
   PubMedGoogle Scholar
• STEINER M, STEINBERG S, STEWART D et al.: Fluoxetine in the treatment of premenstrual dysphoria. Canadian Fluoxetine/Premenstrual Dysphoria Collaborative Study Group. N Engl. I Med. (1995) 332(23):1529–1534. ••The first large-scale study of SSRIs astreatment for PMDD
   Google Scholar
• DIMMOCK PW, WYATT KM, JONES PW, O'BRIEN PM: Efficacy of selective serotonin-reuptake inhibitors in premenstrual syndrome: a systematic review. Lancet (2000) 356(9236):1131–1136.
   PubMed Web of Science ®Google Scholar
• FREEMAN EW, RICKELS K, SONDHEIMER SJ, POLANSKY M: •• Differential response to antidepressants in women with premenstrual syndrome/premenstrual dysphoric disorder: a randomized controlled trial. Arch. Gen. Psychiatry (1999) 56(10):932–939.
   PubMed Web of Science ®Google Scholar
• EPPERSON CN, HAGA K, MASON GF et al.: Cortical y-aminobutyric acid levels across the menstrual cycle in healthy women and those with premenstrual dysphoric disorder: a proton magnetic resonance spectroscopy study. Arch. Gen. Psychiatry (2002) 59(9):851–858.
   PubMedGoogle Scholar
• HALBREICH U, PETTY F, YONKERS K, KRAMER GL, RUSH AJ, BIBI KW: Low plasma y-aminobutyric acid levels during the late luteal phase of women with premenstrual dysphoric disorder. Am. Psychiatry (1996) 153(5):718–720.
   PubMed Web of Science ®Google Scholar
• BACKSTROM T, HAMMARBACK S, JOHANSSON U-B: Etiological aspects of menstrual cycle linked mood changes. In: The Free Woman Van Hall EV, Everland W (Eds). Parthenon Publishers, Carnforth, UK (1989):625–632.
   Google Scholar
• BACKSTROM T: Neumendocrinology of premenstrual syndrome. Clin. Obstet. Gynecol. (1992) 35(3):612–628.
   PubMedGoogle Scholar
• HAMMARBACK S, EKHOLM UB, BACKSTROM T: Spontaneous anovulation causing disappearance of cyclical symptoms in women with the premenstrual syndrome. Acta Endocrinol. (Copenh ) (1991) 125(2):132–137.
   PubMedGoogle Scholar
• MAGYAR DM, BOYERS SP, MARSHALL JR, ABRAHAM GE: Regular menstrual cycles and premenstrual molimina as indicators of ovulation. °Enter Gynecol. (1979) 53(4):411–414.
   Google Scholar
• BJORN I, BIXO M, NOJD KS, NYBERG S, BACKSTROM T: Negative mood changes during hormone replacement therapy: A comparison between two progestogens. Am. J. Obstet. Gynecol. (2000) 183(6):1419–1426.
   PubMedGoogle Scholar
• ENDICOTT J, NEE J, COHEN J, HALBREICH U: Premenstrual changes: Patterns and correlates of daily ratings. Affect. Disord. (1986) 10:127–135.
   PubMedGoogle Scholar
• RAPKIN AJ, CHANG LC, READING AE: Comparison of retrospective and prospective assessment of premenstrual symptoms. Psycho]. Rep. (1988) 62:55–60.
   PubMed Web of Science ®Google Scholar
• MARVAN ML, CORTES-INIESTRA S: Women's beliefs about the prevalence of premenstrual syndrome and biases in recall of premenstrual changes. Health Psycho]. (2001) 20(4):276–280.
   PubMed Web of Science ®Google Scholar
• FRANK R: The hormonal causes of premenstrual tension. Arch. Neurol. Psychiatry (1931) 26:1053–1057.
   Google Scholar
• CHAKMAKJIAN ZH: A critical assessment of therapy for the premenstrual tension syndrome. J. Reprod. Med. (1983) 28(8):532–538.
   PubMedGoogle Scholar
• MORSE CA, DENNERSTEIN L, FARRELL E, VARNAVIDES K: A comparison of hormone therapy, coping skills training, and relaxation for the relief of premenstrual syndrome. J. Behav. Med. (1991) 14(5):469–489.
   PubMed Web of Science ®Google Scholar
• GOODALE IL, DOMAR AD, BENSON H: Alleviation of premenstrual syndrome symptoms with the relaxation response. Obstet. Gynecol. (1990) 75(4):649–655.
   PubMed Web of Science ®Google Scholar
• JOHNSON SR: Premenstrual syndrome therapy. Clin. Obstet. Gynecol. (1998) 41(2):405–421.
   PubMedGoogle Scholar
• STRAUS JL, VON AMMON CAVANAUGH S: Placebo effects. Issues for clinical practice in psychiatry and medicine. Psychosom. (1996) 37(4):315–326.
   Google Scholar
• SCHMIDT PJ, RUBINOW DR: Placebo effect - how powerful? Fertil. Steril (1993) 59(5):1144–1145.
   PubMedGoogle Scholar
• FREEMAN EW, RICKELS K: Characteristics of placebo responses in medical treatment of premenstrual syndrome. Am. J. Psychiatry(1999) 156(9):1403–1408.
   PubMedGoogle Scholar
• YONKERS KA, CLARK RH, TRIVEDI MH: The psychopharmacological treatment of nonmajor mood disorders. Mod. Probl. Pharmacopsychiaby (1997) 25:146–166.
   PubMedGoogle Scholar
• MAGOS AL, BRIN CAT M, STUDD JWW: Treatment of the premenstrual syndrome by subcutaneous oestradiol implants and cyclical oral norethisterone: Placebo controlled study. Br. Med. J. (1986) 292:1629–1633.
   PubMed Web of Science ®Google Scholar
• ROBERTS AH: 'The powerful placebo' revisited: implications for headache treatment and management. Headache Q. (1994) 5:208–213.
   Google Scholar
• CASPER RE HEARN MT: The effect of hysterectomy and bilateral oophorectomy in women with severe premenstrual syndrome. Am. °Enter Gynecol. (1990) 162(1):105–109.
   PubMedGoogle Scholar
• MUSE KN, CETEL NS, FUTTERMAN LA, YEN SC: The premenstrual syndrome. Effects of 'medical ovariectomy'. N Eng. Med. (1984) 311 (21): 1345–1349. ••Established the importance of ovulationsuppression.
   Google Scholar
• FREEMAN EW, SONDHEIMER SJ, RICKELS K, ALBERT J: Gonadotropin-releasing hormone agonist in treatment of premenstrual symptoms with and without comorbidity of depression: a pilot study. Clin. Psychiatry (1993) 54(5):192–195.
   PubMedGoogle Scholar
• MEZROW G, SHOUPE D, SPICER D, LOBO R, LEUNG B, PIKE M: Depot leuprolide acetate with estrogen and progestin add-back for long-term treatment of premenstrual syndrome. Fertil. Steril (1994) 62(5):932–937.
   PubMedGoogle Scholar
• LEATHER AT, STUDD JW, WATSON NR, HOLLAND EF: The treatment of severe premenstrual syndrome with goserelin with and without 'add-back' estrogen therapy: a placebo-controlled study. Gynecol. Endocrinol. (1999) 13 (1):48–55.
   PubMed Web of Science ®Google Scholar
• WEST CP, HILLIER H: Ovarian suppression with the gonadotrophin-releasing hormone agonist goserelin (Zoladex) in management of the premenstrual tension syndrome. Hum. Reprod. (1994) 9(6):1058–1063.
   PubMedGoogle Scholar
• HUSSAIN SY, MASSIL JH, MATTA WH, SHAW RW, O'BRIEN PM: Buserelin in premenstrual syndrome. Gynecol. Endocrinol. (1992) 6 (1):57–64.
   PubMed Web of Science ®Google Scholar
• SUNDSTROM I, NYBERG S, BIXO M, HAMMARBACK S, BACKSTROM T: Treatment of premenstrual syndrome with gonadotropin-releasing hormone agonist in a low dose regimen. Acta °Enter Gynecol. Scand. (1999) 78(10):891–899.
   PubMedGoogle Scholar
• HAMMARBACK S, BACKSTROM T: Induced anovulation as treatment of premenstrual tension syndrome: a double-blind crossover study with GnRH-agonists versus placebo. Acta aster Gynecol. Scand. (1988) 67:159–166.
   PubMed Web of Science ®Google Scholar
• FREEMAN EW, SONDHEIMER SJ, RICKELS K: Gonadotropin-releasing hormone agonist in the treatment of premenstrual symptoms with and without ongoing dysphoria: a controlled study. Psychopharmacol. Bull. (1997) 33 (2):303–309.
   PubMedGoogle Scholar
• BROWN CS, LING FW, ANDERSEN RN, FARMER RG, ARHEART KL: Efficacy of depot leuprolide in premenstrual syndrome: effect of symptom severity and type in a controlled trial. Obstet. Gynecol. (1994) 84(5):779–786.
   PubMed Web of Science ®Google Scholar
• HELVACIOGLU A, YEOMAN RR, HAZELTON JM, AKSEL S: Premenstrual syndrome and related hormonal changes. Long-acting gonadotropin releasing hormone agonist treatment. Reprod. Med. (1993) 38(11):864–870.
   Google Scholar
• PICKERSGILL A: GnRH agonists and add-back therapy: is there a perfect combination? Br. J. Obstet. Cynaecol (1998) 105(5):475–485.
   Google Scholar
• BARBIERI RL: Gonadotropin-releasing hormone agonists and estrogen-progestogen replacement therapy. Am. Obstet. Cynecol (1990) 162(2):593–595.
   PubMedGoogle Scholar
• PALOMBA S, AFFINITO P, DI CARLO C, BIFULCO G, NAPPI C: Long-term administration of tibolone plus gonadotropin-releasing hormone agonist for the treatment of uterine leiomyomas: effectiveness and effects on vasomotor symptoms, bone mass, and lipid profiles. Fertil. Stern. (1999) 72(5):889–895.
   PubMedGoogle Scholar
• ADASHI EY: Long-term gonadotrophin-releasing hormone agonist therapy: the evolving issue of steroidal 'add-back' paradigms. Hum. Reprod. (1994) 9(7):1380–1397.
   PubMedGoogle Scholar
• MORTOLA JF, GIRTON L, FISCHER U: Successful treatment of severe premenstrual syndrome by combined use of gonadotropin-releasing hormone agonist and estrogen/progestin. j Clin. Endocrinol Metab. (1991) 72(2):252A-252F.
   Google Scholar
• SCHMIDT PJ, NIEMAN LK, DANACEAU MA, ADAMS LF, RUBINOW DR: Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome. N Engl. J. Med. (1998) 338(4):209–216.
   PubMed Web of Science ®Google Scholar
• CASPER RF: Estrogen with interrupted progestin HRT: a review of experimental and clinical studies. Maturitas (2000) 34(2):97–108.
   PubMedGoogle Scholar
• MITWALLY ME GOTLIEB L, CASPER RF: Prevention of bone loss and hypoestrogenic symptoms by estrogen and interrupted progestogen add-back in long-term GnRH-agonist down-regulated patients with endometriosis and premenstrual syndrome. Menopause (2002) 9(4):236–241.
   PubMedGoogle Scholar
• KAHN LS, HALBREICH U: Oral contraceptives and mood. Expert Opin. Pharmacother. (2001) 2(9):1367–1382.
   PubMedGoogle Scholar
• GRAHAM CA, SHERWIN BB: A prospective treatment study of premenstrual symptoms using a triphasic oral contraceptive. J. Psychosom. Res. (1992) 36(3):257–266.
   PubMed Web of Science ®Google Scholar
• BACKSTROM T, HANSSON- MALMSTROM Y, LINDHE BA, CAVALLI-BJORKMAN B, NORDENSTROM S: Oral contraceptives in premenstrual syndrome: a randomized comparison of triphasic and monophasic preparations. Contraception (1992) 46(3):253–268.
   PubMedGoogle Scholar
• SULAK PJ, SCOW RD, PREECE C, RIGGS MW, KUEHL TJ: Hormone withdrawal symptoms in oral contraceptive users. Obstet. Cynecol (2000) 95(2):261–266.
   Google Scholar
• WATSON NR, STUDD JW, SAVVAS M, GARNETT T, BABER RJ: Treatment of severe premenstrual syndrome with oestradiol patches and cyclical oral norethisterone. Lancet (1989) 2(8665):730–732.
   PubMedGoogle Scholar
• SMITH RN, STUDD JW, ZAMBLERA D, HOLLAND EF: A randomised comparison over 8 months of 100 micrograms and 200 micrograms twice weekly doses of transdermal oestradiol in the treatment of severe premenstrual syndrome. Brit. J. Obstet. Cynaecol (1995) 102(6):475–484.
   PubMedGoogle Scholar
• DHAR V, MURPHY REP: Double-blind randomized crossover trial of luteal phase estrogens (Premarin) in the premenstrual syndrome (PMS). Psychoneumendocrinol (1991) 15(5 &6):489–493.
   Google Scholar
• BLOCH M, SCHMIDT PJ, RUBINOW DR: Clinical aspects of premenstrual syndrome. Infertil. Reprod. Med. Clin. N Am. (1996) 7:315–329.
   Google Scholar
• WATSON NR, STUDD JW, RIDDLE AF, SAVVAS M: Suppression of ovulation by transdermal oestradiol patches. Br. Med. J. (1988) 297(6653):900–901.
   PubMedGoogle Scholar
• SELAK V, FARQUHAR C, PRENTICE A, SINGLA A: Danazol for pelvic pain associated with endometriosis. Cochrane Database Syst. Rev (2001) 4:CD000068
   Google Scholar
• BARBIERI RL: Danazol: molecular, endocrine, and clinical pharmacology. Frog. Clin. Biol. Res. (1990) 323:241–252.
   PubMedGoogle Scholar
• AGOSTONI A, CICARDI M, MARTIGNONI GC, BERGAMASCHINI L, MARASINI B: Danazol and stanozolol in long-term prophylactic treatment of hereditary angioedema. I Allergy Gin. Immunol (1980) 65(1):75–79.
   PubMedGoogle Scholar
• SARNO AP JR., MILLER EJ JR., LUNDBLAD EG: Premenstrual syndrome: beneficial effects of periodic, low-dose danazol. Obstet. Cynecol (1987) 70(1):33–36.
   Google Scholar
• HALBREICH U, ROJANSKY N, PALTER S: Elimination of ovulation and menstrual cyclicity (with danazol) improves dysphoric premenstrual syndromes. Fertil. (1991) 56(6):1066–1069.
   PubMedGoogle Scholar
• O'BRIEN PM, ABUKHALIL IE: Randomized controlled trial of the management of premenstrual syndrome and premenstrual mastalgia using luteal phase-only danazol. Am. J. Obstet. Cynacol (1999) 180(1, Pt 1):18–23.
   Google Scholar
• GIRDLER SS, PEDERSEN CA, LIGHT KC: Thyroid axis function during the menstrual cycle in women with premenstrual syndrome. Psychoneumendocrinol (1995) 20(4):395–403.
   PubMedGoogle Scholar
• KORZEKWA MI, LAMONT JA, STEINER M: Late luteal phase dysphoric disorder and the thyroid axis revisited. Endocrinol Metab. (1996) 81(6):2280–2284.
   Google Scholar
• SCHMIDT PJ, GROVER GN, ROY-BYRNE PP, RUBINOW DR: Thyroid function in women with premenstrual syndrome. I Gin. Endocrinol Metab. (1993) 76(3):671–674.
   PubMedGoogle Scholar
• NIKOLAI TF, MULLIGAN GM, GRIBBLE RK, HARKINS PG, MEIER PR, ROBERTS RC: Thyroid function and treatment in premenstrual syndrome. Endocrinol Metab. (1990) 70(4):1108–1113.
   Google Scholar
• CASPER RE PATEL- CHRISTOPHERA, POWELL A: Thyrotropin and prolactin responses to thyrotropin-releasing hormone in premenstrual syndrome. Clin. Endocrinol Metab. (1989) 68:608–612.
   Google Scholar
• HALBREICH U, BEN-DAVID M, ASSAEL M, BORNSTEIN R: Serum-prolactin in women with premenstrual syndrome. Lancet (1976) 02(7987):654–656.
   Google Scholar
• GATELEY CA, MANSEL RE: Management of cyclical breast pain. Br. J. Hosp. Med. (1990) 43:330–332.
   PubMedGoogle Scholar
• ADER DN, BROWNE MW: Prevalence and impact of cyclic mastalgia in a United States clinic-based sample. Am. J. Obstet. Cynecol (1997) 177(1):126–132.
   PubMed Web of Science ®Google Scholar
• MCFAYDEN IJ, FORREST AP, CHETTY U, RAAB G: Cyclical breast pain-some observations and the difficulties in treatment. Br. J. Gin. Piaci (1992) 46(3):161–164.
   Google Scholar
• KALELI S, AYDIN Y, EREL CT, COLGAR U: Symptomatic treatment of premenstrual mastalgia in premenopausal women with lisuride maleate: a double-blind placebo-controlled randomized study. Feral. Sterd. (2001) 75(4):718–723.
   PubMed Web of Science ®Google Scholar
• DALTON K: The Premenstrual Syndrome and progesterone therapy 2nd edn. Year Book Medical Publishers, Inc., Chicago, Illinois, USA (1984).
   Google Scholar
• MOLINE ML: Pharmacologic strategies for managing premenstrual syndrome. Clin. Pharm. (1993) 12(3):181–196.
   PubMedGoogle Scholar
• HAMMARBACK S, BACKSTROM T, HOLST J, VON SCHOULTZ B, LYRENAS S: Cyclical mood changes as in the premenstrual tension syndrome during sequential estrogen-progestogen postmenopausal replacement therapy. Acta °Enter Gynecol. Scand. (1985) 64(5):393–397.
   PubMed Web of Science ®Google Scholar
• SCHMIDT PJ, NIEMAN LK, GROVER GN, MULLER KL, MERRIAM GR, RUBINOW DR: Lack of effect of induced menses on symptoms in women with premenstrual syndrome. N Engl. I Med. (1991) 324(17):1174–1179.
   PubMedGoogle Scholar
• RUBINOW DR, HOBAN MC, GROVER GN et al.: Changes in plasma hormones across the menstrual cycle in patients with menstrually related mood disorder and in control subjects. Am." °Enter Gynecol. (1988) 158(1):5–11.
   Google Scholar
• RAPKIN AJ, CHANG LC, READING AE: Premenstrual syndrome: a double blind placebo controlled study of treatment with progesterone vaginal suppositories." Obstet. Gynecol. (1987) 7:217–220.
   Google Scholar
• FREEMAN E, RICKELS K, SONDHEIMER SJ, POLANSKY M: Ineffectiveness of progesterone suppository treatment for premenstrual syndrome: a placebo-controlled, randomized, double-blind study. JAMA (1990) 264:349–353.
   PubMed Web of Science ®Google Scholar
• MADDOCKS S, HAHNP, MOLLERF, REID RL: A double-blind placebo-controlled trial of progesterone vaginal suppositories in the treatment of premenstrual syndrome. Am. J. Obstet. Gynecol. (1986) 154(3):573–581.
   PubMed Web of Science ®Google Scholar
• ANDERSCH B, HAHN L: Progesterone treatment of premenstrual tension - a double-blind study. I Psychosom. Res. (1985) 29(5):489–493.
   PubMedGoogle Scholar
• RICHTER MA, HALTVICK R, SHAPIRO SS: Progesterone treatment of premenstrual syndrome. Curr. Titer. Res. (1984) 36:840–850.
   Google Scholar
• VAN DER MEER YG, BENEDEK- JAZMANN IJ, VAN LOENAN CA: Effect of high dose progesterone on the premenstrual syndrome: a double-blind crossover and placebo. Br. J. Psychiatry (1988) 70(1):33–36.
   Google Scholar
• SAMPSON GA: Premenstrual syndrome: a double-blind controlled trial of progesterone and placebo. Br. J. Psychiatry (1979) 135:209–215.
   PubMed Web of Science ®Google Scholar
• DENNERSTEIN L, SPENCER-GARDNER C, GOTTS G, BROWN JB, SMITH MA, BURROWS GD: Progesterone and the premenstrual syndrome: a double-blind crossover trial. Br. Med. J. (1985) 290:1617–1621.
   PubMed Web of Science ®Google Scholar
• FREEMAN EW, RICKELS K, SONDHEIMER SJ, POLANSKY MP: A double-blind trial of oral progesterone, alprazolam, and placebo in treatment of severe premenstrual syndrome. JAMA (1995) 274(1):51–57.
   PubMedGoogle Scholar
• WYATT K, DIMMOCK P, JONES P, OBHRAI M, O'BRIEN S: Efficacy of progesterone and progestogens in management of premenstrual syndrome: systematic review. Br. Med. J. (2001) 323 (7316):776–780.
   PubMed Web of Science ®Google Scholar
• CASSON P, HAHN PM, VAN VUGT DA, REID RL: Lasting response to ovariectomy in severe intractable premenstrual syndrome. Am. J. °Enter Gynecol. (1990) 162(1):99–105.
   PubMed Web of Science ®Google Scholar
• HALBREICH U, TWOREK H: Altered serotonergic activity in women with dysphoric premenstrual syndromes. Lit. Psychiatry Med. (1993) 23 (1) :1–27.
   PubMed Web of Science ®Google Scholar
• ROJANSKY N, HALBREICH U, ZANDER K, BARKAI A, GOLDSTEIN S: Imipramine receptor binding and serotonin uptake in platelets of women with premenstrual changes. Gynecol. Obstet. Invest. (1991) 31:146–152.
   PubMed Web of Science ®Google Scholar
• ASHBY CR JR., CARR LA, COOK CL, STEPTOE MM, FRANKS DD: Alteration of platelet serotonergic mechanisms and monoamine wddase activity in premenstrual syndrome. Biol. Psychiatry (1988) 24(2):225–233.
   PubMedGoogle Scholar
• COCCARO EF: Central serotonin and impulsive aggression. Br. I Psychiatry Sapp]. (1989) (8):52–62.
   Google Scholar
• MENKES DB, TAGHAVI E, MASON PA, SPEARS GF, HOWARD RC: Fluoxetine treatment of severe premenstrual syndrome. Br. Med. J. (1992) 305(6849):346–347.
   PubMedGoogle Scholar
• STONE AB, PEARLSTEIN TB, BROWN WA: Fluoxetine in the treatment of late luteal phase dysphoric disorder. J. Psychiatry (1991) 52(7):290–293.
   Google Scholar
• WOOD SH, MORTOLA JF, CHAN YE MOOSSAZADEH F, YEN SS: Treatment of premenstrual syndrome with fluoxetine: a double-blind, placebo-controlled, crossover study. Obstet. Gynecol. (1992) 80(3, Pt 1):339–344.
   Google Scholar
• BRANDENBURG S, TUYNMAN-QUA H, VERHEIJ R, PEPPLINKHUIZEN L: Treatment of premenstrual syndrome with fluoxetine: an open study. hat. Clin. Psychopharmacol. (1993) 8(4):315–317.
   PubMed Web of Science ®Google Scholar
• ELKS ML: Open trial of fluoxetine therapy for premenstrual syndrome. South. Med. J. (1993) 86(5):503–507.
   PubMedGoogle Scholar
• PEARLSTEIN TB, STONE AB: Long-term fluoxetine treatment of late luteal phase dysphoric disorder. I. Clin. Psychiatry (1994) 55(8):332–335.
   PubMed Web of Science ®Google Scholar
• SUNDBLAD C, MODIGH K, ANDERSCH B, ERIKSSON E: Clomipramine effectively reduces premenstrual irritability and dysphoria: a placebo-controlled trial. Acta Psychiatr. Scand. (1992) 85(1):39–47.
   PubMed Web of Science ®Google Scholar
• FREEMAN EW, RICKELS K, ARREDONDO F, KAO LC, POLLACK SE, SONDHEIMER SJ: Full- or half-cycle treatment of severe premenstrual syndrome with a serotonergic antidepressant. J. Clin. Psychopharmacol. (1999) 19(1):3–8.
   PubMed Web of Science ®Google Scholar
• HALBREICH U, SMOLLER JW: Intermittent luteal phase sertraline treatment of dysphoric premenstrual syndrome.j Gin. Psychiatry (1997) 58(9)399–402.
   Google Scholar
• YOUNG SA, HURT PH, BENEDEK DM, HOWARD RS: Treatment of premenstrual dysphoric disorder with sertraline during the luteal phase: a randomized, double-blind, placebo-controlled crossover trial. " Clin. Psychiatry (1998) 59(2):76–80.
   Google Scholar
• JERMAIN DM, PREECE CK, SYKES RL, KUEHL TJ, SULAK PJ: Luteal phase sertraline treatment for premenstrual dysphoric disorder. Results of a double-blind, placebo-controlled, crossover study. Arch. Fam. Med. (1999) 8(4):328–332.
   Google Scholar
• HALBREICH U, BERGERON R, YONKERS KA et al.: Efficacy of intermittent, luteal phase sertraline treatment of premenstrual dysphoric disorder. Obstet. Gynecol. (In press).
   Google Scholar
• COHEN L, MINER C, BROWN E et al.: Premenstrual daily fluoxetine for PMDD: a placebo-controlled, clinical trial using computerized diaries. Obstet. Gynecol (2002) 100(3):435–444.
   PubMed Web of Science ®Google Scholar
• MINER C, BROWN E, MCCRAY S, GONZALES J, WOHLREICH M: Weekly luteal-phase dosing with enteric-coated fluoxetine 90 mg in premenstrual dysphoric disorder: a randomized, double-blind, placebo- controlled clinical trial. Chia. The]: (2002) 24(3):417–33.
   PubMed Web of Science ®Google Scholar
• FREEMAN EW, RICKELS K, YONKERS KA, KUNZ NR, MCPHERSON M, UPTON GV: Venlafaxine in the treatment of premenstrual dysphoric disorder. Obstet. Gynecol (2001) 98(5 Pt 1):737–744.
   Google Scholar
• ERIKSSON E, LISJO P, SUNDBLAD C, ANDERSSON K, ANDERSCH B, MODIGH K: Effect of clomipramine on premenstrual syndrome. Acta Psychiatr. Scand. (1990) 81(1):87–88.
   PubMed Web of Science ®Google Scholar
• FREEMAN EW, RICKELS K, SONDHEIMER SJ, DENIS A, PFEIFER S, WEIL S: Nefazodorie in the treatment of premenstrual syndrome: a preliminary study. J. Chia. Psychopharmacol (1994) 14(3):180–186.
   PubMed Web of Science ®Google Scholar
• ERIKSSON E, HEDBERG MA, ANDERSCH B, SUNDBLAD C: The serotonin reuptake inhibitor paroxetin is superior to the noradrenaline reuptake inhibitor maprotiline in the treatment of premenstrual syndrome. Neuropsychopharmacol (1995) 12(2):167–176.
   PubMed Web of Science ®Google Scholar
• HARRISON WM, ENDICOTT J, NEE J: Treatment of premenstrual depression with nortriptyline: a pilot study. J. Chia. Psychiatry (1989) 50(4):136–139.
   PubMedGoogle Scholar
• HARRISON WM, ENDICOTT J, RABKIN JG, NEE JC, SANDBERG D: Treatment of premenstrual dysphoria with alprazolam and placebo. Psychopharmacol Bull. (1987) 23(1):150–153.
   PubMedGoogle Scholar
• HARRISON WM, ENDICOTT J, NEE J: Treatment of premenstrual dysphoria with alprazolam. A controlled study. Arch. Gen. Psychiatry (1990) 47(3):270–275.
   PubMed Web of Science ®Google Scholar
• RICKELS K, FREEMAN E, SONDHEIMER S: Buspirone in treatment of premenstrual syndrome. Lancet (1989) 1(8641)777.
   Google Scholar
• DIEGOLI MS, DA FONSECA AM, DIEGOLI CA, PINOTTI JA: A double-blind trial of four medications to treat severe premenstrual syndrome. hat. J. Gynaecol Obstet. (1998) 62(1):63–67.
   Google Scholar
• PARRY BL, ROSENTHAL NE, TAMARKIN L, WEHR TA: Treatment of a patient with seasonal premenstrual syndrome. Arn. J. Psychiatry (1987) 144(6):762–766.
   PubMed Web of Science ®Google Scholar
• O'BRIEN PM, CRAVEN D, SELBY C, SYMONDS EM: Treatment of premenstrual syndrome by spironolactone. Br: J. Obstet. Gynaecol (1979) 86(2):142–147.
   PubMedGoogle Scholar
• VELLACOTT ID, SHROFF NE, PEARCE MY, STRATFORD ME, AKBAR FA: A double-blind, placebo-controlled evaluation of spironolactone in the premenstrual syndrome. Curc Med. Res. Opin. (1987) 10(7):450–456.
   PubMed Web of Science ®Google Scholar
• WANG M, HAMMARBACK S, LINDHE BA, BACKSTROM T: Treatment of premenstrual syndrome by spironolactone: a double-blind, placebo-controlled study. Acta Obstet. Gynecol Scand. (1995) 74(10):803–808.
   PubMed Web of Science ®Google Scholar
• WOOD C, JAKUBOWICZ D: The treatment of premenstrual symptoms with mefenamic acid. Br. J. Obstet. Gynaecol (1980) 87(7):627–630.
   PubMedGoogle Scholar
• MIRA M, MCNEIL D, FRASER IS, VIZZARD J, ABRAHAM S: Mefenamic acid in the treatment of premenstrual syndrome. Obstet. Gynecol (1986) 68(3):395–398.
   PubMed Web of Science ®Google Scholar
• SANCES G, MARTIGNONI E, FIORONI L, BLANDINI F, FACCHINETTI F, NAPPI G: Naproxen sodium in the treatment of premenstrual symptoms. A placebo- controlled study. Gynecol Obstet. Invest. (1989) 28(4):205–208.
   PubMedGoogle Scholar
• STEINER M, HASKETT RE OSMUN JN, CARROLL BJ: Treatment of premenstrual tension with lithium carbonate. A pilot study. Acta Psychiatr. Scand. (1980) 61(2):96–102.
   PubMed Web of Science ®Google Scholar
• TRUE BL, GOODNER SM, BURNS EA: Review of the etiology and treatment of premenstrual syndrome. Drug Intel] Clin. Pharm. (1985) 19(10):714–722.
   PubMedGoogle Scholar
• SINGER K, CHENG R, SCHOU M: A controlled evaluation of lithium in the premenstrual tension syndrome. Br. J. Psychiatry (1974) 124(578):50–51.
   PubMedGoogle Scholar
• MATTSSON B, VON SCHOULTZ B: A comparison between lithium, placebo and a diuretic in premenstrual tension. Acta Psychiatr. Scand. Sapp] (1974) 255:75–84.
   Google Scholar
• SINGH BB, BERMAN BM, SIMPSON RL, ANNECHILD A: Incidence of premenstrual syndrome and remedy usage: a national probability sample study. Alt. The]: Health Med. (1998) 4(3):75–79.
   PubMedGoogle Scholar
• CORNEY RH, STANTON R: A survey of 658 women who report symptoms of premenstrual syndrome. J. Psychosom. Res. (1991) 35(4-5):471–482.
   PubMedGoogle Scholar
• SAYEGH R, SCHIFF I, WURTMAN J, SPIERS P, MCDERMOTT J, WURTMAN R: The effect of a carbohydrate-rich beverage on mood, appetite, and cognitive function in women with premenstrual syndrome. Obstet. Gynecol (1995) 86(4, Pt 1):520–528.
   Google Scholar
• PRIOR JC, VIGNA Y, SCIARRETTA D, ALOJADO N, SCHULZER M: Conditioning exercise decreases premenstrual symptoms: a prospective, controlled 6-month trial. Feral Stern. (1987) 47(3):402–408.
   PubMed Web of Science ®Google Scholar
• STEEGE JF, BLUMENTHAL JA: The effects of aerobic exercise on premenstrual symptoms in middle-aged women: a preliminary study. J. Psychosom. Res. (1993) 37(2):127–133.
   PubMed Web of Science ®Google Scholar
• THYS-JACOBS S, CECCARELLI S: Calcium Supplementation in premenstrual syndrome: a randomized crossover trial. J. Gen. Intern. Med. (1989) 4:183–189.
   PubMed Web of Science ®Google Scholar
• FACCHINETTI F, BORELLA P, SANCES G, FIORONI L, NAPPI RE, GENAZZANI AR: Oral magnesium successfully relieves premenstrual mood changes. Obstet. Gynecol (1991) 78(2):177–181.
   PubMedGoogle Scholar
• LONDON RS, MURPHY L, KITLOWSKI KE, REYNOLDS MA: Efficacy of a-tocopherol in the treatment of the premenstrual syndrome. J. Reprod. Med. (1987) 32(6):400–404.
   PubMedGoogle Scholar
• WYATT KM, DIMMOCK PW, JONES PW, SHAUGHN O'BRIEN PM: Efficacy of vitamin B6 in the treatment of premenstrual syndrome: systematic review. Br. Med. J. (1999) 318(7195):1375–1381.
   PubMedGoogle Scholar
• USSHER JM: Research and theory related to female reproduction: implications for clinical psychology. Br. J. Gin. Psycho] (1992) 31(Pt 2):129–151.
   Google Scholar
• STEVINSON C, ERNST E: Complementary/alternative therapies for premenstrual syndrome: a systematic review of randomized controlled trials. Am. J. Obstet. Gynecol (2001) 185 (1) :227–235.
   PubMed Web of Science ®Google Scholar
• BUDEIRI D, LI WAN PO A, DORNAN JC: Is evening primrose oil of value in the treatment of premenstrual syndrome? Control. Gin. Trials (1996) 17(1):60–68.
   Web of Science ®Google Scholar
• CAMPBELL EM, PETERKIN D, O'GRADY K, SANSON-FISHER R: Premenstrual symptoms in general practice patients. Prevalence and treatment. Reprod. Med. (1997) 42(10):637–646.
   PubMedGoogle Scholar
• Royal Horticultural Society encyclopedia of plants and flowers. Brickell C (Ed.) Dorling Kindersley, London, UK (1989).
   Google Scholar
• DU MEE C: Vitex agnus castus. Aust. J. Med. Herbalism (1993) 5 :63–65.
   Google Scholar
• HOBBS C: The chaste tree: Vitex agnus castus. Pharm Hist. (1991) 33(1):19–24.
   PubMedGoogle Scholar
• MILEWICZ A, GEJDEL E, SWOREN H et al.: Vitex agnus castus extract in the treatment of luteal phase defects due to latent hyperprolactinemia. Results of a randomized placebo-controlled double-blind study. Arzneimittelforschung (1993) 43(7):752–675.
   Google Scholar
• SLIUTZ G, SPEISER P, SCHULTZ AM, SPONA J, ZEILLINGER R: Agnus castus extracts inhibit prolactin secretion of rat pituitary cells. Harm. Metab. Res. (1993) 25(5):253–255.
   PubMedGoogle Scholar
• LAURITZEN C, REUTER HD, REPGES R, BOHNERT KJ, SCHMIDT U: Treatment of premenstrual syndrome with vitex agnus castus — controlled, double-blind study versus pyridoxine. Phytomed. (1997) 4:183–189.
   PubMed Web of Science ®Google Scholar
• SCHELLENBERG R: Treatment for the premenstrual syndrome with agnus castus fruit extract: prospective, randomised, placebo controlled study. Br. Med. J. (2001) 322(7279):134–137.
   PubMedGoogle Scholar
• HUDDLESTON M, JACKSON EA: Is an extract of the fruit of agnus castus (chaste tree or chasteberry) effective for prevention of symptoms of premenstrual syndrome (PMS)?j Fam. Pract. (2001) 50(4):298.
   Google Scholar
• LOCH EG, SELLE H, BOBLITZ N: Treatment of premenstrual syndrome with a phytopharmaceutical formulation containing Vitex agnus castus. Womens Health Gend. Based Med. (2000) 9(3):315–20.
   PubMedGoogle Scholar